Ramsahai J Michael, Molnar Christine, Lou Lawrence, Ying Winston, MacEachern Paul, Hergott Christopher A, Dumoulin Elaine, Strilchuk Nadine, Fortin Marc, Tremblay Alain
Division of Respiratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Dept of Medical Imaging, Alberta Health Services, Calgary, AB, Canada.
ERJ Open Res. 2020 Oct 5;6(4). doi: 10.1183/23120541.00103-2020. eCollection 2020 Oct.
Proper staging of the mediastinum is an essential component of lung cancer evaluation. Positron emission tomography-computed tomography (PETCT) and endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) are an integral part of this process. False-positive PETCT results can occur following surgical procedures but has not been demonstrated following EBUS-TBNA. We aimed to determine whether false-positive PETCT rates increase when EBUS-TBNA is performed prior to PETCT.
A retrospective review was carried out of clinical cases that underwent both PETCT and EBUS-TBNA within 30 days for the suspected malignancy. The impact of test sequence on the PETCT false-positive rate (FPR) was determined using Generalised Estimating Equation logistic regression analysis.
A total of 675 lymph node stations were sampled and imaged on PETCT. Overall, 332 (49.2%) nodes were sampled by EBUS-TBNA before PETCT, and 343 (50.8%) afterwards, with the interval between EBUS and subsequent PETCT being a mean±sd of 11.6±6.8 days (range 1-29). The FPR on qualitative PETCT for the EBUS first group was 41 (23.2%) out of 164, and for PETCT first it was 57 (29.0%) out of 193 for a difference of 5.8% (95% CI -3.4-14.7, p=0.22). In the regression model, EBUS as the first test was associated with a lower FPR when using the clinical PETCT interpretation.
The performance of EBUS-TBNA sampling did not influence the FPR of PETCT when bronchoscopy took place in the 30 days prior to testing. Test sequence should be selected based on other clinical considerations.
纵隔的准确分期是肺癌评估的重要组成部分。正电子发射断层扫描-计算机断层扫描(PETCT)和支气管内超声引导下经支气管针吸活检(EBUS-TBNA)是这一过程不可或缺的部分。PETCT结果在手术后可能出现假阳性,但在EBUS-TBNA后尚未得到证实。我们旨在确定在PETCT之前进行EBUS-TBNA时,PETCT假阳性率是否会增加。
对30天内因疑似恶性肿瘤而同时接受PETCT和EBUS-TBNA检查的临床病例进行回顾性分析。使用广义估计方程逻辑回归分析确定检查顺序对PETCT假阳性率(FPR)的影响。
总共对675个淋巴结站进行了PETCT采样和成像。总体而言,332个(49.2%)淋巴结在PETCT之前通过EBUS-TBNA采样,343个(50.8%)在之后采样,EBUS与随后的PETCT之间的间隔平均为11.6±6.8天(范围1-29天)。EBUS先做组的定性PETCT的FPR为164个中有41个(23.2%),PETCT先做组为193个中有57个(29.0%),差异为5.8%(95%CI -3.4-14.7,p=0.22)。在回归模型中,当采用临床PETCT解释时,EBUS作为首次检查与较低的FPR相关。
在检查前30天内进行支气管镜检查时,EBUS-TBNA采样的操作并不影响PETCT的FPR。应根据其他临床因素选择检查顺序。